Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Immunotherapy With Low-Dose IL-2/CD25 Prevents β-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice

Farhan M. Qureshi, Julia K. Panzer, Janika Põder, Thomas R. Malek, Alejandro Caicedo

Diabetes 2023;72(6):769–780

https://doi.org/10.2337/db22-0482

Published: 20 March 2023

View article titled, Immunotherapy With Low-Dose IL-2/CD25 Prevents β-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice

Journal Articles

Multicomponent Plasmid Protects Mice From Spontaneous Autoimmune Diabetes

Philippe P. Pagni, Jay Chaplin, Michael Wijaranakula, Johnna D. Wesley, Jaimie Granger, Justen Cracraft, Conor O’Brien, Nikole Perdue, Vijetha Kumar, Shangjin Li, Sowbarnika Sachithanantham Ratliff, Allie Roach, Ayesha Misquith, Chung-leung Chan, Ken Coppieters, Matthias von Herrath

Diabetes 2022;71(1):157–169

https://doi.org/10.2337/db21-0327

Published: 13 August 2021

View article titled, Multicomponent Plasmid Protects Mice From Spontaneous Autoimmune Diabetes

Journal Articles

Impaired Activated/Memory Regulatory T Cell Clonal Expansion Instigates Diabetes in NOD Mice

Vanessa Mhanna, Gwladys Fourcade, Pierre Barennes, Valentin Quiniou, Hang P. Pham, Paul-Gydeon Ritvo, Faustine Brimaud, Bruno Gouritin, Guillaume Churlaud, Adrien Six, Encarnita Mariotti-Ferrandiz, David Klatzmann

Diabetes 2021;70(4):976–985

https://doi.org/10.2337/db20-0896

Published: 21 January 2021

View article titled, Impaired Activated/Memory Regulatory T Cell Clonal Expansion Instigates Diabetes in NOD Mice

Journal Articles

Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms

Natasha C. Ward, Jen Bon Lui, Rosmely Hernandez, Liping Yu, Mary Struthers, Jenny Xie, Alicia Santos Savio, Connor J. Dwyer, Sunnie Hsiung, Aixin Yu, Thomas R. Malek

Diabetes 2020;69(11):2400–2413

https://doi.org/10.2337/db20-0186

Published: 25 August 2020

View article titled, Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms

Journal Articles

Low-Dose Interleukin-2 Combined With Rapamycin Led to an Expansion of CD4⁺CD25⁺FOXP3⁺ Regulatory T Cells and Prolonged Human Islet Allograft Survival in Humanized Mice

Min Hu, Wayne J. Hawthorne, Leigh Nicholson, Heather Burns, Yi Wen Qian, David Liuwantara, Elvira Jimenez Vera, Yi Vee Chew, Lindy Williams, Shounan Yi, Karen Keung, Debbie Watson, Natasha Rogers, Stephen I. Alexander, Philip J. O’Connell

Diabetes 2020;69(8):1735–1748

https://doi.org/10.2337/db19-0525

Published: 07 May 2020

View article titled, Low-Dose Interleukin-2 Combined With Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Regulatory T Cells and Prolonged Human Islet Allograft Survival in Humanized Mice

Meeting Abstracts

253-LB: Effect of Combined Low Dose IL-2 plus Polyclonal Tregs in Type 1 Diabetes Patients

SHEN DONG, CODY T. MOWERY, KEVAN C. HEROLD, STEPHEN E. GITELMAN, JONATHAN H. ESENSTEN, WEIHONG LIU, ANGELA P. LARES, ASHLEY S. LEINBACH, MICHAEL R. LEE, VINH Q. NGUYEN, AMY L. PUTNAM, JIMMIE YE, QIZHI TANG, JEFFREY BLUESTONE

Diabetes 2019;68(Supplement_1):253-LB

https://doi.org/10.2337/db19-253-LB

Published: 01 June 2019

View article titled, 253-LB: Effect of Combined Low Dose IL-2 plus Polyclonal Tregs in Type 1 Diabetes Patients

Journal Articles

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression

Tania Habib, S. Alice Long, Peter L. Samuels, Archana Brahmandam, Megan Tatum, Andrew Funk, Anne M. Hocking, Karen Cerosaletti, Michael T. Mason, Elizabeth Whalen, David J. Rawlings, Carla Greenbaum, Jane H. Buckner, the Type 1 Diabetes TrialNet Study Group

Diabetes 2019;68(6):1240–1250

https://doi.org/10.2337/db18-1081

Published: 20 March 2019

View article titled, Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression

Includes: Supplementary data

Meeting Abstracts

Selectively Agonizing Treg in Type 1 Diabetes with IL-2 Muteins

LILIANE KHORYATI, SWARNIMA KUMARI, THI MINH NGUYET PHAM, MARIKA BOGDANI, MARC GAVIN

Diabetes 2018;67(Supplement_1):314-OR

https://doi.org/10.2337/db18-314-OR

Published: 01 July 2018

View article titled, Selectively Agonizing Treg in Type 1 Diabetes with IL-2 Muteins

Meeting Abstracts

“Alarming" T-Regulatory Cells (Tregs) to Protect from Type 1 Diabetes (T1D)

RAHUL SHARMA, VIKRAM SABAPATHY

Diabetes 2018;67(Supplement_1):227-LB

https://doi.org/10.2337/db18-227-LB

Published: 01 July 2018

View article titled, “Alarming" T-Regulatory Cells (Tregs) to Protect from Type 1 Diabetes (T1D)

Meeting Abstracts

Low-Dose IL-2 Signaling Is Specifically Impaired in Regulatory T Cells from T1D Patients

BARBARA PRIETL, SELINA KOFLER, STEFANIE STANZER, BARBARA M. OBERMAYER-PIETSCH, THOMAS R. PIEBER, HARALD SOURIJ

Diabetes 2018;67(Supplement_1):101-OR

https://doi.org/10.2337/db18-101-OR

Published: 01 July 2018

View article titled, Low-Dose IL-2 Signaling Is Specifically Impaired in Regulatory T Cells from T1D Patients

Journal Articles

UBASH3A Mediates Risk for Type 1 Diabetes Through Inhibition of T-Cell Receptor–Induced NF-κB Signaling

Yan Ge, Taylor K. Paisie, Jeremy R.B. Newman, Lauren M. McIntyre, Patrick Concannon

Diabetes 2017;66(7):2033–2043

https://doi.org/10.2337/db16-1023

Published: 15 June 2017

View article titled, UBASH3A Mediates Risk for Type 1 Diabetes Through Inhibition of T-Cell Receptor–Induced NF-κB Signaling

Includes: Supplementary data

Journal Articles

Comment on Yang et al. Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes. Diabetes 2015;64:3891–3902

Sanja Glisic, Soumitra Ghosh

Diabetes 2016;65(4):e21

https://doi.org/10.2337/db15-1396

Published: 17 March 2016

View article titled, Comment on Yang et al. Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes. Diabetes 2015;64:3891–3902

Journal Articles

Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes

Jennie H.M. Yang, Antony J. Cutler, Ricardo C. Ferreira, James L. Reading, Nicholas J. Cooper, Chris Wallace, Pamela Clarke, Deborah J. Smyth, Christopher S. Boyce, Guo-Jian Gao, John A. Todd, Linda S. Wicker, Timothy I.M. Tree

Diabetes 2015;64(11):3891–3902

https://doi.org/10.2337/db15-0516

Published: 29 July 2015

View article titled, Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes

Includes: Supplementary data

Journal Articles

In This Issue of Diabetes

Diabetes 2015;64(6):1869–1870

https://doi.org/10.2337/db15-ti06

Published: 16 May 2015

View article titled, In This Issue of Diabetes

Journal Articles

Therapeutic Window of Interleukin-2 for Autoimmune Diseases

Qizhi Tang

Diabetes 2015;64(6):1912–1913

https://doi.org/10.2337/db15-0188

Published: 16 May 2015

View article titled, Therapeutic Window of Interleukin-2 for Autoimmune Diseases

Journal Articles

Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

Aixin Yu, Isaac Snowhite, Francesco Vendrame, Michelle Rosenzwajg, David Klatzmann, Alberto Pugliese, Thomas R. Malek

Diabetes 2015;64(6):2172–2183

https://doi.org/10.2337/db14-1322

Published: 09 January 2015

View article titled, Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

Includes: Supplementary data

Journal Articles

Soluble Factors Secreted by T Cells Promote β-Cell Proliferation

Ercument Dirice, Sevim Kahraman, Wenyu Jiang, Abdelfattah El Ouaamari, Dario F. De Jesus, Adrian K.K. Teo, Jiang Hu, Dan Kawamori, Jason L. Gaglia, Diane Mathis, Rohit N. Kulkarni

Diabetes 2014;63(1):188–202

https://doi.org/10.2337/db13-0204

Published: 13 December 2013

View article titled, Soluble Factors Secreted by T Cells Promote β-Cell Proliferation

Includes: Supplementary data

Journal Articles

β-Cell–Specific IL-2 Therapy Increases Islet Foxp3⁺Treg and Suppresses Type 1 Diabetes in NOD Mice

Mark C. Johnson, Alaina L. Garland, Sarah C. Nicolson, Chengwen Li, R. Jude Samulski, Bo Wang, Roland Tisch

Diabetes 2013;62(11):3775–3784

https://doi.org/10.2337/db13-0669

Published: 18 October 2013

View article titled, β-Cell–Specific IL-2 Therapy Increases Islet Foxp3+Treg and Suppresses Type 1 Diabetes in NOD Mice

Includes: Supplementary data

Journal Articles

Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes

Audrey Baeyens, Louis Pérol, Gwladys Fourcade, Nicolas Cagnard, Wassila Carpentier, Janine Woytschak, Onur Boyman, Agnès Hartemann, Eliane Piaggio

Diabetes 2013;62(9):3120–3131

https://doi.org/10.2337/db13-0214

Published: 15 August 2013

View article titled, Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes

Includes: Supplementary data

Journal Articles

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

S. Alice Long, Mary Rieck, Srinath Sanda, Jennifer B. Bollyky, Peter L. Samuels, Robin Goland, Andrew Ahmann, Alex Rabinovitch, Sudeepta Aggarwal, Deborah Phippard, Laurence A. Turka, Mario R. Ehlers, Peter J. Bianchine, Karen D. Boyle, Steven A. Adah, Jeffrey A. Bluestone, Jane H. Buckner, Carla J. Greenbaum

Diabetes 2012;61(9):2340–2348

https://doi.org/10.2337/db12-0049

Published: 17 August 2012

View article titled, Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

Includes: Supplementary data

NARROW

Immunotherapy With Low-Dose IL-2/CD25 Prevents β-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice

Multicomponent Plasmid Protects Mice From Spontaneous Autoimmune Diabetes

Impaired Activated/Memory Regulatory T Cell Clonal Expansion Instigates Diabetes in NOD Mice

Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms

Low-Dose Interleukin-2 Combined With Rapamycin Led to an Expansion of CD4⁺CD25⁺FOXP3⁺ Regulatory T Cells and Prolonged Human Islet Allograft Survival in Humanized Mice

253-LB: Effect of Combined Low Dose IL-2 plus Polyclonal Tregs in Type 1 Diabetes Patients

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression

Selectively Agonizing Treg in Type 1 Diabetes with IL-2 Muteins

“Alarming" T-Regulatory Cells (Tregs) to Protect from Type 1 Diabetes (T1D)

Low-Dose IL-2 Signaling Is Specifically Impaired in Regulatory T Cells from T1D Patients

UBASH3A Mediates Risk for Type 1 Diabetes Through Inhibition of T-Cell Receptor–Induced NF-κB Signaling

Comment on Yang et al. Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes. Diabetes 2015;64:3891–3902

Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes

In This Issue of Diabetes

Therapeutic Window of Interleukin-2 for Autoimmune Diseases

Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

Soluble Factors Secreted by T Cells Promote β-Cell Proliferation

β-Cell–Specific IL-2 Therapy Increases Islet Foxp3⁺Treg and Suppresses Type 1 Diabetes in NOD Mice

Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only